🫀For all the cardiology fellows starting call, I wanted to share this #ECGchallenge published in @JACCJournals #JACCCaseReports #tweetorial 27-year-old woman presented with palpitations. What does her ECG show?

To accompany the new ACC/AHA BP guidelines, a practical guide on how to test for Primary Aldosteronism: now recommended for most people with hypertension. https://t.co/a0FTNTx1Wh

#DIGITHF "A Renaissance for Cardiac Glycosides" Bravo @JBauersachsMD👏🏾 Shape of KM curve reflecting: - Long enrollment '15-'23 (all curves converge eventually!) - High risk cohort (NYHA III/IV) - High study drug discontinuation (~55%) - Few pts studied beyond 5y #ESCCongress

#BaxHTN A New Drug for Resistant or Uncontrolled Hypertension ✅ 9-10mmHg early SBP lowering on background Rx, even w lower doses (1mg) ✅ Remarkably ongoing BP effects & aldo suppression 8wks after withdrawal ✅ ASIs actively being studied in HF prevention, HFrEF, HFpEF, & CKD

The AQUATIC trial may be the most definitive trial of #ESCCOngress The common combo of ASA and OAC for pts with CAD/stent and AF is clearly been harming people. Lots. MACE worse, Death worse, Bleeding way worse. STOP THE ASA when on OAC https://t.co/OSx0UKWPXe

When will any meeting have the King come to our meetings to thank us for the work! With an addition of a shout out to Prevention #CVPrev #ESCCongress @escardio

For patients with resistant or difficult to control HTN, baxdrostat, an Aldosterone synthase inhibitor had a 10 mmHG blood pressure drop at 12 weeks 4/4

3/4

AQUATIC In pts with CAD (>6 months after stent) and AF, OAC alone resulted in less major bleeding and less MACE/CV death than OAC and aspirin, with a NNH of 46 patients, contributing to evidence for the OAC alone strategy for chronic CAD and AF

A couple more important studies at #ESCCongress2025 1/4

POTCAST RCT 📌 In 👫 with #ICD, a strategy to ⬆️ plasma #potassium levels to the high-normal range by means of potassium 💊supplementation or mineralocorticoid receptor antagonist 💊 administration 👉 ⬇️ risk of #VentricularArrhythmias #EPeeps #CardioTwitter #MedTwitter #SCD

📌 Is #BetaBlocker💊 Tx after #MI effective in👫w/ preserved LVEF w/out HF❓ 👉 Contrastant results of 2 #RCTs, REBOOT-CNIC & BETAMI–DANBLOCK, presented at #ESC2025 🔷 Who is right❓ #CardioTwitter #MedTwitter @mmamas1973 @DrMarthaGulati @Hragy @CMichaelGibson @DrPascalMeier

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

Special thanks to @worldheartfed co-author @satheesh_gautam, chairs Drs. Tom Gaziano, @adriannakmurphy , Habib Gamra and the rest of the wonderful team Pablo Perel, Mark Huffman, Pedro Ordunez, @LanaRaspail for this collaboration - stay tuned for more on #CVD polypills!

Last (but most important), we analyze barriers to implementation across three domains: availability, affordability & adoption. In each case, we describe both current obstacles and propose practical solutions to overcome them, and promote widespread adoption of the #CVD polypill.

Next, we provide in-depth analyses of the large cardiovascular outcomes trials for primary & secondary #CVD prevention (HOPE-3, Poly-Iran, TIPS-3, & SECURE) and resulting meta-analyses, which consistently show better efficacy and cost-effectiveness, compared to individual drugs.

First, we cover the history behind the polypill innovation for #CVD, since its ideation in 2000 and through the several #RCT that showed significant improvement in medication adherence ➡️ risk factor control (#Hypertension, #cholesterol) ➡️ reduction in death and adverse events.

#ESCCongress #WCCardio 2025 in #Madrid: excited to launch the @worldheartfed "Roadmap on Single Pill Combination Therapies" for primary & secondary prevention of #CVD #Hypertension #cholesterol, which were included in the 2023 @WHO Essential Medicine List: https://t.co/2UBJR8jWd8

Conflicting data from REBOOT and BETAMI-DANBLOCK regarding use of beta blockers after MI in preserved LVEF (both published in NEJM), however meta-analysis of trials of mildly reduced LVEF 40-49% shows consistent benefit to beta blockers in this population 4/4

MAPLE-HCM shows Aficamten monotherapy superior to metoprolol monotherapy in symptomatic oHCM patients in improving exercise capacity, symptoms, LVOT gradient, NT proBNP. Could support a paradigm shift to myosin inhibitors as initial therapy for LVOTO? 3/4